MRSN vs. ARCT, APLT, ORIC, SRRK, REPL, WVE, HUMA, YMAB, ATXS, and PHVS
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Arcturus Therapeutics (ARCT), Applied Therapeutics (APLT), ORIC Pharmaceuticals (ORIC), Scholar Rock (SRRK), Replimune Group (REPL), Wave Life Sciences (WVE), Humacyte (HUMA), Y-mAbs Therapeutics (YMAB), Astria Therapeutics (ATXS), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.
Arcturus Therapeutics (NASDAQ:ARCT) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking.
Arcturus Therapeutics has a beta of 2.6, meaning that its share price is 160% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are held by institutional investors. 13.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 11.8% of Mersana Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Arcturus Therapeutics presently has a consensus price target of $71.40, suggesting a potential upside of 275.79%. Mersana Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 300.00%. Given Mersana Therapeutics' higher possible upside, analysts plainly believe Mersana Therapeutics is more favorable than Arcturus Therapeutics.
Arcturus Therapeutics has a net margin of -41.21% compared to Mersana Therapeutics' net margin of -349.98%. Arcturus Therapeutics' return on equity of -25.47% beat Mersana Therapeutics' return on equity.
Arcturus Therapeutics received 186 more outperform votes than Mersana Therapeutics when rated by MarketBeat users. However, 65.78% of users gave Mersana Therapeutics an outperform vote while only 65.76% of users gave Arcturus Therapeutics an outperform vote.
Arcturus Therapeutics has higher revenue and earnings than Mersana Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Arcturus Therapeutics had 5 more articles in the media than Mersana Therapeutics. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 1 mentions for Mersana Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.11 beat Mersana Therapeutics' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media.
Summary
Arcturus Therapeutics beats Mersana Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
